ObsEva (NASDAQ:OBSV) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

ObsEva Stock Performance

ObsEva has a 12-month low of $0.08 and a 12-month high of $2.14. The company has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68. The stock has a 50-day simple moving average of $0.01.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.